Bioventure has extended its strategic partnership with Adalvo, the global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, by signing a licensing deal for four molecules, within the MENA region.

The products are indicated in a variety of treatments including oncology, urinary tract infection, and anti-infective.

With this collaboration, Adalvo is now able to offer over 30 products within GCC & North Africa, extending its coverage within the region.

Ashraf Radwan, CEO of the Healthcare Division, said: “Collaboration with Adalvo is another step forward in the development and patient access improvement in the MENA region. We look forward to contributing to patients’ well-being and expanding the variety and affordability of required high-quality treatments, with our strategic partner – Adalvo.”

Adalvo is expecting to continue strengthening its position within this market, providing patients with high-quality and affordable options for their treatments, together with our partners.

Anil Okay, CEO at Adalvo, comments: “We are thrilled to be extending our strategic collaboration with Bioventure, with the addition of four differentiated molecules. Bioventure has been an early supporter of Adalvo, ever since our inception and this longstanding partnership is key in further strengthening our commercial presence across the globe. We look forward to working with Bioventure to bring essential treatments to patients”.